Methods Homocitrullinated peptides were identified and assessed in vitro for HLA-A2 binding and in vivo in human leukocyte antigen (HLA) transgenic mouse models for immunogenicity. (bmj.com)
Each chain contains three complementarity-determining regions (CDR1-CDR3), which contribute to antigen specificity. (bvsalud.org)
Peptides3
Recent observations raise the hypothesis that not only the drug/chemical, but also parts of the haptenated protein or peptides may constitute the important structural determinants for antigen recognition by the TCR. (frontiersin.org)
Modified peptides showed enhanced binding to HLA-A2 compared with the native sequences and immunization of HLA-A2 transgenic mice generated high avidity modification specific CD8 responses that killed peptide expressing target cells. (bmj.com)
The allelic variations among different HLA molecules are a major factor accounting for differences in the types of antigenic peptides to which an individual responds or in the types of T cells that are used in an immune response. (musculoskeletalkey.com)
Molecules5
The HLA molecules and their counterparts in rodents were subsequently shown to be directly responsible for immune response differences between individuals and for determining the likelihood of graft rejection. (musculoskeletalkey.com)
In each individual, T cells are generally restricted to recognize antigens presented by the person's own HLA molecules. (musculoskeletalkey.com)
HLA class I molecules consist of a 45-kD α chain encoded within the MHC that is noncovalently associated with the 12-kD β 2 -microglobulin chain (encoded on chromosome 15). (musculoskeletalkey.com)
HLA class II molecules consist of noncovalently associated α (32 kD) and β (28 kD) chains, both of which are encoded within the MHC. (musculoskeletalkey.com)
HLA class I and class II molecules are cell surface glycoproteins, anchored to the membrane by hydrophobic transmembrane segments. (musculoskeletalkey.com)
Naive3
During thymic selection, T cells that have not yet encountered their cognate antigen are considered naive T cells. (frontiersin.org)
We show that for naive antibodies (those not yet adapted to antigens), the probability that they use the same light chain V gene is around 10%, whereas for memory (functional) antibodies, it is around 80%, even if only one cell per clonotype is used. (bvsalud.org)
Thus, although naive antibodies seem to recur by chance, the recurrence of functional antibodies reveals surprising constraint and determinism in the processes of V(D)J recombination and immune selection. (bvsalud.org)
Immune3
Background Post-translational modification of proteins has the potential to alter the ability of T cells to recognize major histocompatibility complex (MHC) class -I and class-II restricted antigens, thereby resulting in altered immune responses. (bmj.com)
The innate immune system develops in utero and, unlike the adaptive (acquired) immune system , does not require imprinting or adaptation to specific antigens nor does it provide permanent pathogen -specific immunity . (amboss.com)
The vertebrate adaptive immune system modifies the genome of individual B cells to encode antibodies that bind particular antigens 1 . (bvsalud.org)
Recognize1
Activated B cells and memory T cells can recognize specific antigens on pathogens. (amboss.com)
Gene1
In most mammals, antibodies are composed of heavy and light chains that are generated sequentially by recombination of V, D (for heavy chains), J and C gene segments. (bvsalud.org)
Processes1
Produced by eosinophils in response to antibody -dependent processes (e.g. (amboss.com)
Responses1
Interestingly, the recent data in RA indicate that the major HLA-DR associations are with anti-CCP antibody positive disease, suggesting that control of autoantibody responses may be a primary mechanism underlying these associations in RA as well. (musculoskeletalkey.com)
Chains1
Certain heavy and light chains are preferred for particular antigens 2-22 . (bvsalud.org)
Class1
In the case of systemic lupus erythematosus (SLE) and related illnesses, many of the HLA class II alleles are associated with the presence of specific autoantibodies or clinical phenotypes. (musculoskeletalkey.com)
Cells1
Due to the artificial nature of drug/chemical-T-cell epitopes, it is not clear whether thymic selection of drug/chemical-specific T cells is a common phenomenon or remains limited to few donors or simply does not exist, suggesting T-cell receptor (TCR) cross-reactivity with other antigens. (frontiersin.org)
Memory1
Memory response becomes more potent and faster after subsequent exposures to an antigen . (amboss.com)
Cell2
We screened the circulating B cell repertoires of COVID-19 survivors and vaccinees using multiplexed panels of uniquely barcoded antigens in a high-throughput single cell workflow to isolate over 9,000 SARS-CoV-2-specific monoclonal Abs (mAbs), providing an expansive view of the SARS-CoV-2-specific Ab repertoire. (bvsalud.org)
The polymorphisms associated with the "shared epitope" are located on the α-helical rim (DRB1 chain) of the peptide-binding cleft, where they may interact with either the bound peptide antigen or the T cell receptor. (musculoskeletalkey.com)
Peptide2
7. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. (nih.gov)
14. The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells. (nih.gov)
Human leukocyte antigen (HLA) haplotype DQ2 or DQ8 identified by molecular genetic testing of HLA-DQA1 and HLA-DQB1 . (nih.gov)
Types1
We compared the usefulness of myositis-specific autoantibodies (anti-aminoacyl-tRNA synthetases, anti-SRP, anti-Mi-2 and anti-MAS) to the standard clinical categories (polymyositis, dermatomyositis, overlap myositis, cancer-associated myositis, and inclusion body myositis) in predicting clinical signs and symptoms, HLA types, and prognosis in 212 adult IIM patients. (nih.gov)
Patients2
4. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer. (nih.gov)
15. Wildtype p53-specific antibody and T-cell responses in cancer patients. (nih.gov)